Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919178 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
A Phase 1 study of Dengue Hemorrhagic Fever and Dengue Shock Syndrome, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT00919178 is a Phase 1 study of Dengue Hemorrhagic Fever and Dengue Shock Syndrome that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 70 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00919178, a Phase 1 study of Dengue Hemorrhagic Fever and Dengue Shock Syndrome, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties. The World Health Organization (WHO) estimates that these viruses are responsible for more than 50 million cases of dengue fever (DF) and approximately 0.5 million cases of the more severe disease, dengue hemorrhagic fever/ shock syndrome (DHF/DSS) annually. Because dengue viruses are endemic in most tropical and subtropical regions, keeping more than 2 billion persons at risk for acquiring dengue, the WHO has made development of a dengue vaccine a top priority. The purpose of this study is to evaluate the safety and effectiveness of a candidate DEN4 vaccine aimed at preventing infection with dengue virus serotype 4.
Conditions Studied
Interventions
- BIOLOGICAL DEN4 Vaccine Candidate
- BIOLOGICAL DEN4 Vaccine Placebo
Study Locations (2)
Maryland
- Center for Immunization Research, Johns Hopkins School of Public Health - Baltimore
Vermont
- University of Vermont Vaccine Testing Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919178
The ClinicalTrials.gov registry entry for NCT00919178 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dengue Hemorrhagic Fever appearing as the primary indexed condition, and to 2 interventions - of which DEN4 Vaccine Candidate is the first listed.
NCT00919178 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Vermont.
Frequently Asked Questions
What is clinical trial NCT00919178 about?
NCT00919178 is a clinical study titled "Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus". Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties. The World Health Organization (WHO) estimates that these viruses are responsible for more than 50 million cases of dengue fever (DF) and approximately 0.5 million c...
What is the current status of trial NCT00919178?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2009-07. Estimated completion is 2010-05.
What conditions does trial NCT00919178 study?
This clinical trial studies the following conditions: Dengue Hemorrhagic Fever, Dengue Shock Syndrome.
What interventions are being tested in trial NCT00919178?
The interventions under investigation include: DEN4 Vaccine Candidate (BIOLOGICAL), DEN4 Vaccine Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00919178?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00919178 being conducted?
This trial has 2 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue Hemorrhagic Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.